ILIsabel León

Isabel León

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabel León has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aetiologic spectrum of longitudinally extensive spinal cord lesions and clues to their differential diagnosis

    by María Puche-Ribera, Pablo Arroyo-Pereiro, Isabel León, Laura Bau, Elisabet Matas, Lucía Romero-Pinel, Francisco Morandeira, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos, Albert Muñoz-Vendrell

  • Open Access

    Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis

    by Albert Muñoz-Vendrell, Pablo Arroyo-Pereiro, Isabel León, Laura Bau, Elisabet Matas, Lucia Romero-Pinel, Sergio Roca-Pereira, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos

    Background: Subcutaneous natalizumab offers greater convenience than intravenous administration, but pharmacokinetic differences have raised concerns about potential subclinical disease activity. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are sensitive biomarkers of neuroaxonal damage and astroglial activation. Methods: In this prospective, single-center cohort study, consecutive patients with relapsing–remitting multiple sclerosis who transitioned from intravenous to subcutaneous natalizumab were followed for 12 months. Serum sNfL and GFAP were measured at baseline (prior to switch), and at 6 and 12 months using SIMOA technology. Additional clinical outcomes included annualized relapse rate (ARR), EDSS, and MRI activity. Results: 23 patients were included (mean age 43.7 years; 91% female). Median disease duration was 14 years (IQR 8.1–22), median time on natalizumab was 5 years (IQR 3.3–7.9), baseline 2-year ARR was 0.09 ± 0.2, and median EDSS was 2.0 (IQR 2.0–3.5). Median sNfL Z -scores were 0.2 (IQR − 0.3–0.6) at baseline, 0.1 (IQR − 0.4–1.0) at 6 months, and 0.5 (IQR − 0.4–1.1) at 12 months, with no significant change over time ( p = 0.401). GFAP levels were similarly stable (87.7, 86.8, and 90.2 pg/mL; p = 0.957). ARR remained low and unchanged (0.09 pre- and post-switch; p = 1.0), with no radiological activity observed. EDSS remained stable over follow-up. Conclusions: In this small real-world cohort, switching from intravenous to subcutaneous natalizumab was associated with stable sNfL and GFAP levels over 12 months, alongside stable conventional clinical and MRI outcomes. These findings provide supplementary biomarker evidence broadly consistent with existing clinical trial and real-world data, but should be interpreted cautiously given the small sample size.

  • Open Access

    Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

    by Sergio Roca‐Pereira, Yaiza López‐Sampere, Pol Mengod‐Soler, Mario Peña‐Fonteboa, Carla Marco, Alejandro Caravaca‐Puchades, Raúl Domínguez, Juan Francisco Vázquez‐Costa, Enrique Santamaría, Joaquín Fernández‐Irigoyen, et al.

    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease primarily affecting motor neurons. Neurofilament light chain (NfL) is the most established prognostic biomarker; however, its diagnostic resolution is limited, particularly within intermediate concentration ranges, and it does not capture the molecular heterogeneity of ALS. This study aimed to identify complementary cerebrospinal fluid (CSF) biomarkers and pathway‐specific signatures through a non‐targeted multiomic approach. We performed SWATH‐MS‐based proteomics and LC–MS/MS lipidomics on CSF from ALS patients stratified by survival (ALS‐SS and ALS‐LS) and healthy controls. Weighted protein co‐expression network analysis (WPCNA) was applied to identify biologically coherent protein modules associated with disease phenotype and progression. Top biomarker candidates were further evaluated using immunoassays in an independent cohort. Post‐mortem ALS spinal cord tissues were analyzed to explore the pathophysiological relevance of identified proteins. CSF proteomic profiles robustly distinguished ALS patients from controls and stratified patient subgroups by survival, revealing a molecular signature characterized by inflammation, downregulation of detoxification mechanisms, and synaptic dysregulation in aggressive disease forms. In contrast, lipidomic profiles showed limited discriminatory power. WPCNA identified modular proteomic signatures capturing ALS heterogeneity, and machine learning models based on these profiles yielded optimal biomarker panels for diagnosis and prognosis. CXCL7 emerged as a promising complementary biomarker, and shed light in disease physiopathology. Immunoassay validation supported the diagnostic and prognostic potential of CXCL7 and its association with survival time. Histopathological analysis further confirmed CXCL7 localization in anterior horn motor neurons, despite no detectable changes in whole spinal cord lysates at late disease stages. Comprehensive CSF proteomic profiling, combined with network‐based analysis, enhances our understanding of ALS molecular heterogeneity and provides a framework for precision biomarker discovery. CXCL7 complements NfL as a diagnostic and prognostic biomarker, supporting improved patient stratification and advancing the development of personalized therapeutic strategies in ALS.

  • Open Access

    Benign multiple sclerosis and long-term outcomes after 30 years

    by E. Matas, L. Bau, L. Romero-Pinel, I. León, P. Arroyo-Pereiro, A. Muñoz-Vendrell, A. Martínez-Yélamos, S. Martínez-Yélamos

    Background: The concept of benign multiple sclerosis (MS) is a matter of debate. In most definitions, only the Expanded Disability Status Scale (EDSS) score and disease duration are considered, although other factors may influence a patient’s disability. The aims of this study were to evaluate the percentage of patients with benign MS in our cohort and to determine the proportion of these patients who remained benign after 20 and 30 years of disease evolution. Clinical and demographic variables related to this outcome were investigated. Methods: Patients fulfilling the criteria for benign MS (EDSS < 3.0 and at least 10 years of MS evolution) were selected from a hospital-based series and followed up prospectively. The EDSS was assessed after 20 and 30 years of MS evolution. Clinical and radiological variables were evaluated. Fatigue, depression and cognition tests were performed. Results: Eighty-two of the 485 patients evaluated in 1996 fulfilled the criteria for benign MS and were selected. In 51 of the 68 (75%) patients evaluated in 2006, the EDSS score continued to be ≤ 3. In 2016, 35 out of 58 (60%) patients continued to have an EDSS score ≤ 3. None of the clinical variables could predict persistence in the benign group. Eighteen of the 35 benign MS patients completed the questionnaires after 30 years. Fifty percent of them reported fatigue, 22% depression, and 83% had cognitive impairment. Conclusion: The majority of MS patients maintained a benign status even after 30 years of disease evolution. However, cognitive impairment in this group is notable.


  • Open Access

    The 2024 McDonald criteria show comparable sensitivity to previous criteria for late-onset multiple sclerosis

    by Raquel Tena-Cucala, Pablo Naval-Baudin, Antonio Martínez-Yélamos, Isabel León, Albert Muñoz-Vendrell, Laura Bau, Elisabet Matas, Pablo Arroyo-Pereiro, Alejandro Caravaca Puchades, Francisco Morandeira, et al.


  • Open Access

    Assessment of the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort

    by Laura Bau, Elisabet Matas, Lucía Romero-Pinel, Isabel León, Albert Muñoz-Vendrell, Pablo Arroyo-Pereiro, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos

    Background: People with multiple sclerosis (MS) present varying degrees of disability throughout their disease course. The Multiple Sclerosis Severity Score (MSSS) and the Age-Related Multiple Sclerosis Severity Score (ARMSSS) adjust the Expanded Disability Status Scale (EDSS) according to disease duration and age, respectively. These measures could be useful for quantifying MS severity and as health outcome indicators for benchmarking in population-based settings. The aim of this study was to describe the severity of MS in our health district using the MSSS and ARMSSS and to assess their consistency over time. Methods: This population-based study included patients from our health district who were diagnosed with MS according to the 2010 McDonald criteria, had a disease duration of at least one year and were followed up in our MS unit. Sex, age at onset, disease duration, clinical course, age and irreversible EDSS at the last follow-up visit were collected, and the MSSS and ARMSSS were calculated at two time points: 2017 and 2020. Results: One hundred seventy-seven patients were included in 2017, and 208 in 2020. The prevalence of MS was 90 and 104 per 100,000 inhabitants, respectively. The median MSSS was 1.77 (IQR 0.76–4.28) in 2017 and 2.03 (IQR 0.82–4.36) in 2020. The median ARMSSS was 2.90 (IQR 1.47–5.72) in 2017 and 2.93 (IQR 1.51–5.56) in 2020. No significant differences were found. Conclusions: According to the MSSS and ARMSSS, the severity of MS in our area is mild, and these instruments are consistent. These measures could be reliable health outcome measures.


  • Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis

    by Álvaro Cobo-Calvo, Agnes Figueras, Laura Bau, Elisabet Matas, María Alba Mañé Martínez, Isabel León, Carles Majòs, Lucia Romero-Pinel, Sergio Martínez-Yélamos